TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22654645

Group type: EXPERIMENTAL
Intervention: Strength training with whole body vibration (WBV) - f = 35 Hz, A = 2.5 mm
Number of subjects: 12

Group type: COMPARATOR
Intervention: Strength training without whole body vibration (Control)
Number of subjects: 12
Study: 20730368

Group type: EXPERIMENTAL
Intervention: Aquatic exercise group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Non-aquatic exercise group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 18319306

Group type: EXPERIMENTAL
Intervention: Metformin (425 mg/d for 2 yr, then 850 mg/d for 2 yr)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 38
Study: 15944074

Group type: EXPERIMENTAL
Intervention: Salmonella typhi vaccine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12886210

Group type: EXPERIMENTAL
Intervention: Thermocycling for 500 cycles between 5 degrees and 55 degrees C with a dwell time of 30 seconds
Number of subjects: 120

Group type: COMPARATOR
Intervention: No thermocycling treatment
Number of subjects: 120
Study: 10073863

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein (HDL) raising treatment with nicotinic acid
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein (LDL) lowering therapy with hydroxymethylglutaryl-coenzyme A reductase inhibitor
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Antioxidant therapy (beta-carotene and vitamins E and C)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy (warfarin)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Combination of interventions
Number of subjects: 468

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 468
Study: 8898629

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 2213

Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 2213
Study: 1798006

Group type: EXPERIMENTAL
Intervention: Lacidipine 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6336634

Group type: EXPERIMENTAL
Intervention: Cranial irradiation
Number of subjects: 21

Group type: COMPARATOR
Intervention: No cranial irradiation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cranial irradiation (non-randomized group)
Number of subjects: 21
Study: 31746224

Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 0
Study: 30827869

Group type: EXPERIMENTAL
Intervention: Self-selected walking group (SSWG; n = 25)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (CG; n = 23)
Number of subjects: 48
Study: 29599033

Group type: COMPARATOR
Intervention: Liposomal bupivacaine (EXP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ropivacaine cocktail (ROP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both EXP and ROP
Number of subjects: 32
Study: 27351443

Group type: EXPERIMENTAL
Intervention: Ayurvedic program
Number of subjects: 69

Group type: COMPARATOR
Intervention: Vacation group
Number of subjects: 69
Study: 24939380

Group type: EXPERIMENTAL
Intervention: Electrothermal arthroscopic capsulorrhaphy (ETAC)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Open inferior capsular shift (ICS)
Number of subjects: 54
Study: 22078631

Group type: EXPERIMENTAL
Intervention: Physiological modulators (PMs) with antioxidant action (MF Templar®)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: MF Templar®
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Green tea (same amount of catechins as MF Templar®)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: MF Templar® devoid of catechins
Number of subjects: 64
Study: 19605967

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HFRT) - 57 Gy in 13 fractions of 3 Gy plus 4 fractions of 4.5 Gy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy (CFRT) - 74 Gy in 37 fractions (2 Gy per fraction)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HFRT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy (CFRT)
Number of subjects: 91
Study: 17890871

Group type: EXPERIMENTAL
Intervention: Continuous frusemide infusion
Number of subjects: 59

Group type: COMPARATOR
Intervention: Regular intermittent intravenous boluses of frusemide
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 59
Study: 15388575

Group type: EXPERIMENTAL
Intervention: Fondaparinux (Arixtra)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 54
Study: 11993614

Group type: EXPERIMENTAL
Intervention: human alphaCGRP (2 microg/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 9696954

Group type: EXPERIMENTAL
Intervention: Controlled-release levodopa/carbidopa 200/50 mg after a standard meal (30 min before ingestion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Controlled-release levodopa/carbidopa 200/50 mg after fasting (2 hours after ingestion)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Controlled-release levodopa/carbidopa 200/50 mg after a standard meal
Number of subjects: 8

Group type: COMPARATOR
Intervention: Controlled-release levodopa/carbidopa 200/50 mg after fasting
Number of subjects: 8
Study: 7584018

Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing (annual screening)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing and sigmoidoscopy (early detection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing (case-control study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sigmoidoscopy screening
Number of subjects: 0
Study: 2497982

Group type: EXPERIMENTAL
Intervention: Minitran
Number of subjects: 63

Group type: COMPARATOR
Intervention: Transderm-Nitro (TDN)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 63
Study: 29629694

Group type: EXPERIMENTAL
Intervention: Gastric lavage with normal saline at 10 mL per kg body weight (n=350)
Number of subjects: 700

Group type: COMPARATOR
Intervention: No gastric lavage (n=350)
Number of subjects: 700
Study: 28681047

Group type: EXPERIMENTAL
Intervention: Tea sweetened with stevia
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tea sweetened with sucrose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tea sweetened with jaggery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unsweetened tea (control)
Number of subjects: 24
Study: 25512179

Group type: EXPERIMENTAL
Intervention: Couple-based HIV counseling and testing intervention
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard‐of‐care individual HIV testing and counseling intervention
Number of subjects: 220
Study: 23448313

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine prescription from clinician A
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine prescription from clinician B
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine prescription from clinician C
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 300
Study: 21189109

Group type: EXPERIMENTAL
Intervention: Electrochemically deposited hydroxyapatite (Bonemaster)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Plasma-sprayed hydroxyapatite
Number of subjects: 50
Study: 19877978

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Olanzapine + Topiramate
Number of subjects: 40
Study: 16968585

Group type: EXPERIMENTAL
Intervention: NXY-059 (8-h and 72-h intravenous infusions)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (8-h and 72-h intravenous infusions)
Number of subjects: 104
Study: 12531493

Group type: EXPERIMENTAL
Intervention: Head-down neck extension (HDNE) during lower body negative pressure (LBNP; -40 mmHg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Head-down neck flexion (HDNF) during lower body negative pressure (LBNP; -40 mmHg)
Number of subjects: 9
Study: 12224577

Group type: EXPERIMENTAL
Intervention: sulfadoxine/pyrimethamine plus artesunate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: gametocyte-positive isolates free of subpatent trophozoites
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: gametocyte-only isolates
Number of subjects: 30
Study: 10806684

Group type: EXPERIMENTAL
Intervention: Third party leukocyte immunization
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Paternal leukocyte immunization
Number of subjects: 40
Study: 8030596

Group type: EXPERIMENTAL
Intervention: Partially hydrogenated soybean oil
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Sunflower oil
Number of subjects: 61
Study: 2722729

Group type: EXPERIMENTAL
Intervention: Cefmetazole (3 doses of 1 g)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Cefoxitin (3 doses of 2 g)
Number of subjects: 69
Study: 31532321

Group type: EXPERIMENTAL
Intervention: Endometrial scratching (ES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No scratch (control)
Number of subjects: 0
Study: 28606382

Group type: EXPERIMENTAL
Intervention: Caya with ContraGel
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caya with 3% Nonoxynol-9 (N-9)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caya alone
Number of subjects: 9
Study: 25363381

Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-I
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-II
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Myeloperoxidase
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-IV
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Apolipoprotein B-100
Number of subjects: 22
Study: 23517585

Group type: EXPERIMENTAL
Intervention: CPAP therapy for at least two months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Baseline OSA patients
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Peak vascular response following breath hold tests in OSA patients before CPAP therapy
Number of subjects: 23
Study: 22364032

Group type: EXPERIMENTAL
Intervention: Buphenine, aminophenazone and diphenylpyraline hydrochloride
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 20205010

Group type: EXPERIMENTAL
Intervention: Values affirmation condition
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Kindness affirmation condition
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Positive traits affirmation condition
Number of subjects: 162

Group type: COMPARATOR
Intervention: No affirmation control condition
Number of subjects: 162
Study: 17114014

Group type: EXPERIMENTAL
Intervention: Pancreatic duct stenting (S)
Number of subjects: 238

Group type: COMPARATOR
Intervention: No stent (NS)
Number of subjects: 238
Study: 15031595

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization (TAE)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Transcatheter arterial infusion chemotherapy (TAI)
Number of subjects: 168
Study: 11223117

Group type: EXPERIMENTAL
Intervention: Bromperidol (6, 12, or 18 mg/day for 3 weeks)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nemonapride (18 mg/day for 3 weeks)
Number of subjects: 52
Study: 9407637

Group type: EXPERIMENTAL
Intervention: Assays for the detection of human parvovirus B19 DNA using PCR techniques; Sensitivity varied among laboratories: 2 laboratories detected the 10(-7) dilution, 1 laboratory failed to detect B19 DNA in any samples, and 5 laboratories obtained false-positive results.
Number of subjects: 17
Study: 8425670

Group type: EXPERIMENTAL
Intervention: Ponalrestat 600 mg once daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 31982096

Group type: EXPERIMENTAL
Intervention: Combined treatment of Parent Management Training (PMT) and child Cognitive Behavioral Therapy (CBT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined treatment of PMT and child CBT
Number of subjects: 120

Group type: COMPARATOR
Intervention: PMT only
Number of subjects: 120
Study: 30735332

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50000 IU per week for 8-12 weeks)
Number of subjects: 26
Study: 29265084

Group type: EXPERIMENTAL
Intervention: Noophen with standard therapy (n=33)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard therapy only (Control group, n=20)
Number of subjects: 53
Study: 25451990

Group type: EXPERIMENTAL
Intervention: Web-based interactive genetics curriculum
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (genetics review articles)
Number of subjects: 121
Study: 23783056

Group type: EXPERIMENTAL
Intervention: Suction on (‐75 mmHg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Suction on (‐125 mmHg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Suction on (‐400 mmHg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dressing on, no suction
Number of subjects: 6
Study: 21306285

Group type: EXPERIMENTAL
Intervention: Proactive multifactorial risk factor intervention strategy using single‐pill amlodipine/atorvastatin (5/10, 10/10 mg)
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: Proactive multifactorial risk factor intervention
Number of subjects: 1461
Study: 18769080

Group type: EXPERIMENTAL
Intervention: Midazolam 50 microg/kg with normal saline 1 ml/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% 1 ml/kg
Number of subjects: 50
Study: 16818967

Group type: EXPERIMENTAL
Intervention: rhBMP-2/allograft
Number of subjects: 30

Group type: COMPARATOR
Intervention: autogenous bone graft
Number of subjects: 30
Study: 14614669

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin ointment, twice daily for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin ointment
Number of subjects: 0
Study: 10781652

Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy with oral 17beta-estradiol or transdermal 17beta-estradiol, and oral norethisterone.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (healthy women).
Number of subjects: 26
Study: 8835111

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 0
Study: 1482629

Group type: EXPERIMENTAL
Intervention: DermaMend
Number of subjects: 0

Group type: COMPARATOR
Intervention: A & D
Number of subjects: 0
Study: 3975045

Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Number of subjects: 10

Group type: COMPARATOR
Intervention: Spectacle correction
Number of subjects: 10
Study: 31348235

Group type: EXPERIMENTAL
Intervention: Group-focused rational emotive behavior coaching (REBC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study: 30208857

Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS) sessions (bipolar, 85 Hz) 2×/week for 12 weeks
Number of subjects: 131

Group type: COMPARATOR
Intervention: Usual care control group receiving individualized nutritional support
Number of subjects: 131
Study: 26449959

Group type: EXPERIMENTAL
Intervention: Methylergonovine and oxytocin infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxytocin infusion only
Number of subjects: 0
Study: 25467005

Group type: EXPERIMENTAL
Intervention: Dietary intervention group advised to reduce insoluble dietary fiber and lactose intake
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard care group advised to continue their usual diet
Number of subjects: 130
Study: 22257710

Group type: COMPARATOR
Intervention: Low transvalvular gradients (≤40 mm Hg)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: High transvalvular gradients (>40 mm Hg)
Number of subjects: 270
Study: 23155514

Group type: EXPERIMENTAL
Intervention: Severe recurrent major depression (n=5)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control subjects with negligible symptoms of depression (n=4)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Random non-clinical sample of women (n=40)
Number of subjects: 45
Study: 17337179

Group type: EXPERIMENTAL
Intervention: Hand-held Neurotip tester pin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neuropen (spring loaded system)
Number of subjects: 0
Study: 16358163

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Sedation (PCS) with midazolam: loading dose 0.028 mg/kg, bolus dose 1 mg, lock-out period 5 min, basal infusion rate 0.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group received 1 microg/kg of fentanyl (i.v.) and 0.028 mg/kg of midazolam (i.v.).
Number of subjects: 40
Study: 11942259

Group type: EXPERIMENTAL
Intervention: Computerized firm system approach with point-of-service reminders and pharmacist outreach program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computerized firm system approach
Number of subjects: 0
Study: 9585654

Group type: EXPERIMENTAL
Intervention: Adderall 5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adderall 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adderall 15 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adderall 20 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Methylphenidate (positive control)
Number of subjects: 30
Study: 7815676

Group type: EXPERIMENTAL
Intervention: Long-chain triglycerides (LCTs) infusion (0.07 g/kg.h‐1)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCTs) and long-chain triglycerides (LCTs) mixture infusion (50/50%, 0.07 g/kg.h‐1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (glucose infusion only)
Number of subjects: 19
Study: 2651632

Group type: EXPERIMENTAL
Intervention: Cimetidine (30‐40 mg/kg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 786504

Group type: EXPERIMENTAL
Intervention: Visible disfigurement (photograph of a girl with post‐operative disfigurement)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Normal speaker (audio recording)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nasal speaker (audio recording)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Retouched photograph (eliminating disfigurement)
Number of subjects: 60
Study: 31690495

Group type: EXPERIMENTAL
Intervention: Long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs)
Number of subjects: 304
Study: 31129092

Group type: EXPERIMENTAL
Intervention: Firehawk stent
Number of subjects: 1653

Group type: COMPARATOR
Intervention: XIENCE stent
Number of subjects: 1653
Study: 28399076

Group type: EXPERIMENTAL
Intervention: Intensive 10-day health promotion program combining diet and physical activities
Number of subjects: 30
Study: 25808741

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2029

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2029
Study: 23657156

Group type: EXPERIMENTAL
Intervention: High-phytochemical diet rich in cruciferous vegetables, citrus, and soya (F&V)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fruit- and vegetable-free (basal) diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tertiles of crucifers, citrus, and soya intake based on 3 d food records
Number of subjects: 10

Group type: COMPARATOR
Intervention: Tertiles of total fruit and vegetable intake for FFQ
Number of subjects: 10
Study: 21367952

Group type: EXPERIMENTAL
Intervention: Obese individuals (BMI ≥30)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nonobese individuals (BMI <30)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Normal-weight individuals (BMI 18-25)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 81

Group type: COMPARATOR
Intervention: Men
Number of subjects: 81
Study: 19125855

Group type: EXPERIMENTAL
Intervention: Amlodipine/atorvastatin (5/20 mg) plus therapeutic lifestyle changes (TLC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus therapeutic lifestyle changes (TLC)
Number of subjects: 0
Study: 16959151

Group type: EXPERIMENTAL
Intervention: Rapid fluid resuscitation
Number of subjects: 38

Group type: COMPARATOR
Intervention: General treatment
Number of subjects: 38
Study: 14708463

Group type: EXPERIMENTAL
Intervention: Virtual Colonoscopy (VC)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Conventional Colonoscopy (CC)
Number of subjects: 500
Study: 11198157

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with ketorolac
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard group with conventional analgesia (ketorolac I.V. 0.5 mg/kg/6 hours)
Number of subjects: 0
Study: 9176747

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 day 1, etoposide 130 mg/m2 days 1‐3
Number of subjects: 87

Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2, vinblastine 6 mg/m2, mitomycin 10 mg/m2 day 1
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cisplatin-etoposide
Number of subjects: 87

Group type: COMPARATOR
Intervention: Cisplatin-mitomycin-vinblastine
Number of subjects: 87
Study: 1548947

Group type: EXPERIMENTAL
Intervention: Prednisone only (group I)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Defined formula diet (Vital HN) only (group II)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of prednisone and Vital HN (group III)
Number of subjects: 27
Study: 3697832

Group type: EXPERIMENTAL
Intervention: Alpha-methyldopa
Number of subjects: 5

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 5
Study: 31620924

Group type: EXPERIMENTAL
Intervention: VIE intervention (multidisciplinary program including physical activity, nutritional, and psychological interventions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (only one evaluation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VIE intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30375639

Group type: EXPERIMENTAL
Intervention: Evidence-based ecological intervention (storytelling, discussion, drawing, dramatization)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Evidence-based ecological intervention
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 206